Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Company Logo Dublin, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The "Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2020-2024" report has been added to ...

Royalty Pharma plc (NASDAQ:RPRX), a leading funder of innovation across the biopharmaceutical industry with a market capitalization of $19.25 billion and an impressive 99% gross profit margin ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition ... small and mid-cap biotechnology companies to ...

Biotechnology startups historically have relied on top pharmaceutical companies to make acquisition bids. Now a new class of buyers is emerging. Smaller drugmakers increasingly are joining the ...

The acquisition follows a research collaboration between Taiho Pharmaceutical and Araris signed in November 2023 and is expected to be completed in the first half of 2025. Under the terms of the ...

Otsuka Pharmaceutical is broadening its scope ... to treat the spectrum of PKU patients from mild to severe disease. The acquisition agreement comes six months after the biotech announced JNT ...

Kissei Pharmaceutical Co ( (JP:4547)) has shared an update. Kissei Pharmaceutical Co., Ltd. has completed the acquisition of 1,369,200 treasury shares, representing 3.20% of its issued shares ...

The introduction of COVID-19 vaccinations in 2020 caused the biotech industry to soar to prominence. As Big Pharma started investing in acquisitions, investor interest increased in late 2023 and ...

Royalty Pharma plc continues to demonstrate its commitment to growth and expansion within the pharmaceutical sector with this latest strategic acquisition. The transaction is expected to further ...